PWM
NPCE icon

Palumbo Wealth Management’s Neuropace NPCE Stock Holding History

Palumbo Wealth Management’s Portfolio NPCE Stock Details NPCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.32M Sell
209,199
-1,270
-0.6% -$20.4K 0.7% 30
2026
Q1 		$2.77M Sell
210,469
-3,706
-2% -$55.6K 0.68% 33
2025
Q4 		$3.31M Buy
214,175
+16,699
+8% +$223K 0.82% 30
2025
Q3 		$2.04M Buy
197,476
+27,586
+16% +$260K 0.65% 38
2025
Q2 		$1.89M Buy
169,890
+123,779
+268% +$1.55M 0.59% 45
2025
Q1 		$567K Buy
46,111
+34,594
+300% +$433K 0.19% 84
2024
Q4 		$129K Buy
+11,517
New +$100K 0.05% 165

Other funds holding NPCE

PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Palumbo Wealth Management's NPCE Position: Q2 2026 in Review

Palumbo Wealth Management reduced its Neuropace (NPCE) stake by 0.6% in Q2 2026, selling an estimated $20.4K and leaving 209,199 shares worth $3.32M. The position accounts for 0.7% of the portfolio, ranked #30.

Palumbo Wealth Management first reported a position in NPCE in Q4 2024 and has held it in 7 quarters since. 113 funds tracked by Wall St. Rank hold NPCE as of Q2 2026.

  • Palumbo Wealth Management held 209,199 shares of Neuropace worth $3.32M as of Q2 2026.
  • Palumbo Wealth Management sold 1,270 Neuropace shares in Q2 2026, an estimated $20.4K.
  • Neuropace made up 0.7% of Palumbo Wealth Management's portfolio in Q2 2026, its #30 holding.
  • Palumbo Wealth Management first reported a position in Neuropace in Q4 2024 and has held it in 7 quarters since.
  • 113 funds tracked by Wall St. Rank held Neuropace as of Q2 2026.

Based on Palumbo Wealth Management's 13F filing for Q2 2026, filed 12 Aug 2026.